Nandan Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 11 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.03 Cr
as on 24-10-2024
- Revenue -27.46%
(FY 2023)
- Profit -55.31%
(FY 2023)
- Ebitda -17.78%
(FY 2023)
- Net Worth 9.64%
(FY 2023)
- Total Assets 14.97%
(FY 2023)
About Nandan Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.03 Cr.
Anshu Gupta and Dhiraj Gupta serve as directors at the Company.
- CIN/LLPIN
U51101MH2013PTC239311
- Company No.
239311
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jan 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Nandan Pharma Private Limited offer?
Nandan Pharma Private Limited offers a wide range of products and services, including Brain & Nervous System Drugs, Antiepileptic Drugs, Anti Infective Drugs & Medicines, Antibiotic Injection, Pain Relief Drugs & Pharmaceuticals, Anesthetic, Psychotherapeutic Agents, Digestive System Drugs & Medicines, Antispasmodic Drugs, Nutraceuticals & Dietary Supplements.
Who are the key members and board of directors at Nandan Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anshu Gupta  | Director | 04-Jan-2013 | Current |
| Dhiraj Gupta | Director | 04-Jan-2013 | Current |
Financial Performance of Nandan Pharma.
Nandan Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 27.46% decrease. The company also saw a substantial fall in profitability, with a 55.31% decrease in profit. The company's net worth moved up by a moderate rise of 9.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nandan Pharma?
In 2023, Nandan Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Well Life Pharmaceuticals Private LimitedActive 14 years 6 monthsAnshu Gupta and Dhiraj Gupta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Nov 2022 | ₹2.00 Cr | Open |
Others Creation Date: 03 Apr 2021 | ₹0.25 M | Open |
How Many Employees Work at Nandan Pharma?
Unlock and access historical data on people associated with Nandan Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nandan Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nandan Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
